Identification

Name
Sennosides
Accession Number
DB11365
Type
Small Molecule
Groups
Experimental
Description

Sennosides (also known as senna glycoside or senna) is a medication used to treat constipationLabel12 and empty the large intestine before surgery. The medication is taken by mouth or via the rectumLabel. It typically begins working in minutes when given by rectum and within twelve hours when given by mouthLabel. It is a weaker laxative than bisacodyl or castor oil11. Sennoside A, one of the sennosides present in the laxative medication, has recently proven effective in inhibiting the ribonuclease H (RNase H) activity of human immunodeficiency virus (HIV) reverse transcriptase 1.

Structure
Thumb
Synonyms
  • Senna
  • Senna glycosides
  • Sennoside
  • Sennosides
Product Ingredients
IngredientUNIICASInChI Key
Sennosides A and B1B5FPI42EN62211-03-4Not applicable
Product Images
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Agarol Extra Strength Chewable Laxative TabletsTabletOralNumark Laboratories, Inc.2000-08-212009-07-31Canada
Agarol With SennosidesLiquidOralNumark Laboratories, Inc.1999-06-302009-07-31Canada
AgoralLiquid8.3 mg/5mLOralNumark Brands, Inc1942-05-052016-10-18Us
Assured Natural LaxativeTablet, coated8.6 mg/1OralSpirit Pharmaceuticals LLC2016-08-122016-07-28Us
Bekunis Natures Gentle Laxative Herbal TeaExtract23 mg/1gOralRoha Arzneimittel Gmbh2011-03-21Not applicableUs
Bekunis Natures Gentle Laxative Instant TeaPowder20 mg/0.5gOralRoha Arzneimittel Gmbh2011-03-21Not applicableUs
Bekunis Natures Gentle Stimulant LaxativeTablet, sugar coated20 mg/1OralRoha Arzneimittel Gmbh2011-02-10Not applicableUs
Best Choice SennaTablet8.6 mg/1OralBest Choice (Valu Merchandisers Company)2012-05-182019-12-31Us
CAREALL SennosidesTablet8.6 mg/1OralNew World Imports2016-04-18Not applicableUs
Castoria Liq 0.7mg/mlLiquidOralThe Mentholatum Company1919-12-311997-11-27Canada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Bekunis DrageesSennosides (60 mg) + Sennosides (20 mg) + Sennosides (25 mg) + Bisacodyl (5 mg)TabletOralRoha Arzneimittel Gmbh1974-12-312009-07-02Canada
Bekunis DrageesSennosides (60 mg) + Sennosides (20 mg) + Sennosides (25 mg) + Bisacodyl (5 mg)TabletOralRoha Arzneimittel Gmbh1974-12-312009-07-02Canada
Bekunis DrageesSennosides (60 mg) + Sennosides (20 mg) + Sennosides (25 mg) + Bisacodyl (5 mg)TabletOralRoha Arzneimittel Gmbh1974-12-312009-07-02Canada
C Ottways Lax TabSennosides (28 mg) + Aloe Vera Leaf (132 mg) + Capsicum (19 mg) + Frangula purshiana bark (28 mg) + Ginger (9 mg) + Glycyrrhiza glabra (28 mg)TabletOralC Ottway Herbalist1950-12-311997-06-13Canada
CAREALL Senna-S LaxativeSennosides (8.6 mg/1) + Docusate sodium (50 mg/1)TabletOralNew World Imports, Inc.2016-04-18Not applicableUs
CennlacsSennosides (726 mg) + Glycyrrhiza glabra (182 mg)PowderOralWestward Distributors1983-12-311997-05-30Canada
CholasynSennosides (12 mg) + Frangula purshiana bark (50 mg)TabletOralRolmex International Inc.1998-06-292001-08-14Canada
Cholasyn IISennosides (25 mg) + Frangula purshiana bark (175 mg)TabletOralRolmex International Inc.1983-12-312008-02-13Canada
ColaceSennosides (8.6 mg/1) + Docusate sodium (50 mg/1)Tablet, film coatedOralAvrio Health L.P.1957-02-08Not applicableUs
ColaceSennosides (8.6 mg/1) + Docusate sodium (50 mg/1)Tablet, film coatedOralAvrio Health L.P.1957-02-08Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Medi-laxx Rx Stool Softener and LaxativeSennosides (8.6 mg/1) + Docusate sodium (50 mg/1)TabletOralTwo Hip Consulting, Llc2014-12-052016-04-11Us
Senna GenSennosides (8.6 mg/1)TabletOralCardinal Health2011-06-072011-06-30Us
Senna PlusSennosides (8.6 mg/1) + Docusate sodium (50 ug/1)TabletOralAmerincan Health Packaging2004-10-282014-08-31Us
Senna PlusSennosides A and B (8.6 mg/1) + Docusate sodium (50 mg/1)Tablet, film coatedOralMajor Pharmaceuticals2010-01-142020-08-31Us
Senna PlusSennosides A and B (8.6 mg/1) + Docusate sodium (50 mg/1)Tablet, film coatedOralCardinal Health2010-01-14Not applicableUs
Senna PlusSennosides (8.6 mg/1) + Docusate sodium (50 mg/1)Tablet, film coatedOralCardinal Health2010-01-142014-10-31Us
Senna-SSennosides (8.6 mg/1) + Docusate sodium (50 mg/1)TabletOralCardinal Health2011-06-032012-05-31Us
Senna-SSennosides (8.6 mg/1) + Docusate sodium (50 mg/1)Tablet, coatedOralPld Acquisitions Llc Dba Avéma Pharma Solutions2010-01-022017-02-28Us
Sennosides and Docusate SodiumSennosides (8.6 mg/1) + Docusate sodium (50 mg/1)TabletOralMcKesson Packaging Services a business unit of McKesson Corporation2007-10-11Not applicableUs
Stool SoftenerSennosides (8.6 mg/1) + Docusate sodium (50 mg/1)Tablet, coatedOralPld Acquisitions Llc Dba Avéma Pharma Solutions2010-01-022017-02-28Us
Categories
UNII
9VK7V8762D
CAS number
517-43-1
Weight
Average: 862.746
Monoisotopic: 862.195643624
Chemical Formula
C42H38O20
InChI Key
IPQVTOJGNYVQEO-UHFFFAOYSA-N
InChI
InChI=1S/C42H38O20/c43-11-23-31(47)35(51)37(53)41(61-23)59-21-5-1-3-15-25(17-7-13(39(55)56)9-19(45)27(17)33(49)29(15)21)26-16-4-2-6-22(60-42-38(54)36(52)32(48)24(12-44)62-42)30(16)34(50)28-18(26)8-14(40(57)58)10-20(28)46/h1-10,23-26,31-32,35-38,41-48,51-54H,11-12H2,(H,55,56)(H,57,58)
IUPAC Name
4,4'-dihydroxy-10,10'-dioxo-5,5'-bis({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy})-9H,9'H,10H,10'H-[9,9'-bianthracene]-2,2'-dicarboxylic acid
SMILES
OCC1OC(OC2=C3C(=O)C4=C(C=C(C=C4O)C(O)=O)C(C4C5=CC=CC(OC6OC(CO)C(O)C(O)C6O)=C5C(=O)C5=C4C=C(C=C5O)C(O)=O)C3=CC=C2)C(O)C(O)C1O

Pharmacology

Indication

For the over the counter treatment of constipationLabel12.

Associated Conditions
Pharmacodynamics

Senna stimulates peristalsis and increases fecal water content to increase motility of feces through the large intestine6,2,12.

Mechanism of action

Sennoside A and B, the components of senna, are metabolized by gut bacteria into the active metabolite rheinanthrone Rheinanthrone2. Rheinanthrone Rheinanthrone appears to increase cyclooxegenase 2 (COX2) expression in macrophage cells leading to an increase in prostaglandin E2 (PGE2)2. This increase in PGE2 is associated with a decrease in aquaporin 3 expression in mucosal epithelial cells of the large intestine2. A decrease in aquaporin 3 expression likely produces the laxative effect by restricting water reabsorption by the large intestine thereby increasing fecal water content2. The exact mechanism by which rheinanthrone increases COX2 expression is unknown2. Rheinanthrone Rheinanthrone also stimulates peristalsis in the large intestine although the mechanism behind this effect is unknown6. Rhein Rhein, another active metabolite is thought to excite submucosal acetylcholinergic neurons resulting in increased chloride and prostaglandin secretion8,9. The movement of chloride ions into the large intestine would also help to draw water into the lumen9.

TargetActionsOrganism
AAquaporin-3
inhibitor
Humans
UReverse transcriptase/RNaseH
inhibitor
Human immunodeficiency virus 1
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

<10% is absorbed from the gut mostly in the form of the active metabolite rheinanthrone [Rheinanthrone](https://www.drugbank.ca/drugs/DB13175)12.

Volume of distribution

The volume of distribution of radiolabelled intravenous sennoside B in rats was 0.802±0.124L/kg10.

Protein binding

Because sennosides are ingested and their action occurs in the gut, it is generally not thought to be protein bound2.

Metabolism

Sennosides A and B are metabolised to sennidins A and B by gut bacteria6. Sennidins A and B are further metabolized to rheinanthrone Rheinanthrone by gut bacteria using beta-glucosidase2. Rheinanthrone Rheinanthrone is absorbed into systemic circulation where 2.6% is metabolized to rhein Rhein and sennidins A and B via oxidation4,7,2. Rheinanthrone Rheinanthrone is the major active metabolite of sennosides A and B which produces the laxative effect of the medication2. Rhein Rhein is also an active metabolite known to have many protective effects8.

Route of elimination

3-6% of metabolites are excreted in urine with some in bile. >90% of sennosides are excreted in the feces as polymers with 2-6% of the parent compounds excreted unchanged12.

Half life

The half life of radiolabelled intravenous sennoside B in rats was 8.568±0.651h10.

Clearance

The clearance of radiolabelled intravenous sennoside B in rats was 0.065±0.007L/h/kg10.

Toxicity

Senna causes increased amounts of apoptosis in the large intestine shortly after use due to upregulated p53 activity3. This is normally reversed after 18 hours however chronic use has been shown to be associated with p53 resistance and potential carcinogenicity leading to colon cancer3. The LD50 value in rats was 5000mg/kg. Subacute studies in rats receiving 20mg/kg and dogs receiving 500mg/kg did not produce signs of toxicity5. Tests for mutagenicity and reproductive toxicity do not indicate toxic effects5.

Sennosides are not recommended for use in pregnancy due to genotoxic risks associated with chemically similar compounds12. The active metabolite of sennosides is excreted in breast milk, though there are no reports of the laxitive effect in breast fed babies12. There is no data on the effects of sennosides on fertility12.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Sennosides.
AclidiniumThe therapeutic efficacy of Sennosides can be decreased when used in combination with Aclidinium.
AgmatineThe therapeutic efficacy of Sennosides can be decreased when used in combination with Agmatine.
AlcuroniumThe therapeutic efficacy of Sennosides can be decreased when used in combination with Alcuronium.
AlfentanilThe therapeutic efficacy of Sennosides can be decreased when used in combination with Alfentanil.
AlloinThe risk or severity of adverse effects can be increased when Sennosides is combined with Alloin.
AlphacetylmethadolThe therapeutic efficacy of Sennosides can be decreased when used in combination with Alphacetylmethadol.
AlphaprodineThe therapeutic efficacy of Sennosides can be decreased when used in combination with Alphaprodine.
AmantadineThe therapeutic efficacy of Sennosides can be decreased when used in combination with Amantadine.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Sennosides.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
  • Avoid natural licorice. Licorice root can induce hypokalemia in patients taking sennosides.

References

General References
  1. Esposito F, Carli I, Del Vecchio C, Xu L, Corona A, Grandi N, Piano D, Maccioni E, Distinto S, Parolin C, Tramontano E: Sennoside A, derived from the traditional chinese medicine plant Rheum L., is a new dual HIV-1 inhibitor effective on HIV-1 replication. Phytomedicine. 2016 Nov 15;23(12):1383-1391. doi: 10.1016/j.phymed.2016.08.001. Epub 2016 Aug 10. [PubMed:27765358]
  2. Kon R, Ikarashi N, Nagoya C, Takayama T, Kusunoki Y, Ishii M, Ueda H, Ochiai W, Machida Y, Sugita K, Sugiyama K: Rheinanthrone, a metabolite of sennoside A, triggers macrophage activation to decrease aquaporin-3 expression in the colon, causing the laxative effect of rhubarb extract. J Ethnopharmacol. 2014 Feb 27;152(1):190-200. doi: 10.1016/j.jep.2013.12.055. Epub 2014 Jan 8. [PubMed:24412547]
  3. van Gorkom BA, Karrenbeld A, van der Sluis T, Zwart N, de Vries EG, Kleibeuker JH: Apoptosis induction by sennoside laxatives in man; escape from a protective mechanism during chronic sennoside use? J Pathol. 2001 Aug;194(4):493-9. [PubMed:11523059]
  4. Dreessen M, Eyssen H, Lemli J: The metabolism of sennosides A and B by the intestinal microflora: in vitro and in vivo studies on the rat and the mouse. J Pharm Pharmacol. 1981 Oct;33(10):679-81. [PubMed:6117629]
  5. Mengs U: Toxic effects of sennosides in laboratory animals and in vitro. Pharmacology. 1988;36 Suppl 1:180-7. [PubMed:3368517]
  6. Hardcastle JD, Wilkins JL: The action of sennosides and related compounds on human colon and rectum. Gut. 1970 Dec;11(12):1038-42. [PubMed:4929273]
  7. de Witte P, Lemli J: Metabolism of 14C-rhein and 14C-rhein anthrone in rats. Pharmacology. 1988;36 Suppl 1:152-7. [PubMed:3368514]
  8. Zhou YX, Xia W, Yue W, Peng C, Rahman K, Zhang H: Rhein: A Review of Pharmacological Activities. Evid Based Complement Alternat Med. 2015;2015:578107. doi: 10.1155/2015/578107. Epub 2015 Jun 22. [PubMed:26185519]
  9. Frieling T, Rupprecht C, Schemann M: Rhein stimulates electrogenic chloride secretion by activation of submucosal neurons in guinea pig colon. Pharmacology. 1993 Oct;47 Suppl 1:70-6. [PubMed:8234445]
  10. Zhang D, Huang D, Ji Y, Jiang C, Li Y, Gao M, Yao N, Liu X, Shao H, Jing S, Ni Y, Yin Z, Zhang J: Experimental evaluation of radioiodinated sennoside B as a necrosis-avid tracer agent. J Drug Target. 2015 Feb;23(2):180-90. doi: 10.3109/1061186X.2014.971328. Epub 2014 Oct 20. [PubMed:25330022]
  11. Portalatin M, Winstead N: Medical management of constipation. Clin Colon Rectal Surg. 2012 Mar;25(1):12-9. doi: 10.1055/s-0032-1301754. [PubMed:23449608]
  12. Senokot Tablet Product Information [Link]
External Links
Human Metabolome Database
HMDB34317
KEGG Compound
C10404
PubChem Substance
347911200
ChemSpider
5010
BindingDB
92481
RxNav
36387
ChEBI
9112
ChEMBL
CHEMBL54481
Wikipedia
Senna_glycoside
ATC Codes
A06AB56 — Senna glycosides, combinationsA06AB06 — Senna glycosides
AHFS Codes
  • 56:12.00 — Cathartics and Laxatives
  • 92:01.00* — Herbs and Natural Products
FDA label
Download (335 KB)
MSDS
Download (34.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentFunctional Constipation / Gastrointestinal Disorder1
2TerminatedTreatmentDiabetic Gastroparesis1
2, 3CompletedTreatmentColonoscopy1
2, 3CompletedTreatmentConstipation1
3CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD) / Dyspnea1
3CompletedTreatmentConstipation2
3RecruitingPreventionMalignant Neoplasm of Colon1
3RecruitingPreventionRectal Cancer Surgery1
3SuspendedTreatmentConstipation1
3Unknown StatusDiagnosticGastrointestinal Hemorrhage / Refractory Anemia / Small Bowel Diseases1
4CompletedNot AvailableColonoscopy Preparation1
4CompletedTreatmentColonoscopy Preparation1
4CompletedTreatmentConstipation1
4RecruitingPreventionConstipation1
4RecruitingTreatmentConstipation / Peritoneal dialysis complication1
4TerminatedNot AvailableColonoscopy Preparation1
4TerminatedSupportive CareConstipation / Malignancies1
4WithdrawnHealth Services ResearchColorectal Cancers1
Not AvailableActive Not RecruitingBasic ScienceIntestinal Transit1
Not AvailableCompletedDiagnosticColorectal Cancer Screening1
Not AvailableCompletedOtherBowel preparation therapy / Colonoscopy / Colonoscopy Preparation Outcome1
Not AvailableCompletedPreventionConstipation / Palliative Care1
Not AvailableCompletedTreatmentAutistic Disorder / Encopresis1
Not AvailableCompletedTreatmentConstipation1
Not AvailableCompletedTreatmentEnd Stage Renal Disease (ESRD) / Pruritus1
Not AvailableNot Yet RecruitingPreventionColostomy Stoma / Hirschprung's Disease / Ileostomy - Stoma / Inflammatory Bowel Diseases (IBD) / Intestinal Obstruction / Jejunostomy Stoma / Meconium Ileus / NEC1
Not AvailableTerminatedTreatmentChronic idiopathic constipation (CIC)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
LiquidOral8.3 mg/5mL
ExtractOral23 mg/1g
PowderOral20 mg/0.5g
Tablet, sugar coatedOral20 mg/1
Powder25 kg/25kg
Powder27 kg/27kg
Tablet, chewableOral8.6 mg/1
Bar, chewableOral15 mg/1
Tablet, chewableOral15 mg/1
LiquidOral25 mg/15mL
PillOral15 mg/1
TabletOral
LiquidOral
ExtractOral1000 mg/1g
PowderOral1000 mg/1g
KitOral
CapsuleOral
TabletOral12 mg/1
Tablet, chewableOral3 mg/1
Tablet, sugar coatedOral25 mg/1
PillOral25 mg/1
TabletOral15 mg
Tablet, coatedOral15 mg/1
Tablet, sugar coatedOral15 mg/1
TabletOral25 mg/1
TabletOral
LiquidOral8.8 mg/1mL
Tablet, coatedOral25 mg/1
TabletOral15 mg/1
CapsuleOral
PowderOral
LiquidOral
Tablet, coatedOral
Capsule, gelatin coatedOral8.6 mg/1
LiquidOral415.36 mg/236mL
SyrupOral417.12 mg/237mL
TabletOral250 mg
Tablet, film coatedOral8.6 mg/1
Tablet, coatedOral8.6 mg/1
ExtractOral0.4 g
Capsule, gelatin coatedOral
TabletOral8.6 mg/1
LiquidOral8.8 mg/5mL
Tablet, film coatedOral
SyrupOral8.8 mg/5mL
Capsule, liquid filledOral17.2 mg/17.21
Capsule, liquid filledOral17.2 mg/1
Tablet, film coatedOral17.2 mg/1
SuppositoryRectal
PillOral
TabletOral17.2 mg/1
JellyOral
CapsuleOral8.3 mg/1
PowderOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.753 mg/mLALOGPS
logP0.94ALOGPS
logP1.19ChemAxon
logS-3.1ALOGPS
pKa (Strongest Acidic)3.23ChemAxon
pKa (Strongest Basic)-4ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count20ChemAxon
Hydrogen Donor Count12ChemAxon
Polar Surface Area347.96 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity205.44 m3·mol-1ChemAxon
Polarizability81.49 Å3ChemAxon
Number of Rings8ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Water channel required to promote glycerol permeability and water transport across cell membranes. Acts as a glycerol transporter in skin and plays an important role in regulating SC (stratum corneum) and epidermal glycerol content. Involved in skin hydration, wound healing, and tumorigenesis. Provides kidney medullary collecting duct with high permeability to water, thereby permitting water to move in the direction of an osmotic gradient. Slightly permeable to urea and may function as a water and urea exit mechanism in antidiuresis in collecting duct cells. It may play an important role in gastrointestinal tract water transport and in glycerol metabolism (By similarity).
Specific Function
Glycerol channel activity
Gene Name
AQP3
Uniprot ID
Q92482
Uniprot Name
Aquaporin-3
Molecular Weight
31543.605 Da
References
  1. Kon R, Ikarashi N, Nagoya C, Takayama T, Kusunoki Y, Ishii M, Ueda H, Ochiai W, Machida Y, Sugita K, Sugiyama K: Rheinanthrone, a metabolite of sennoside A, triggers macrophage activation to decrease aquaporin-3 expression in the colon, causing the laxative effect of rhubarb extract. J Ethnopharmacol. 2014 Feb 27;152(1):190-200. doi: 10.1016/j.jep.2013.12.055. Epub 2014 Jan 8. [PubMed:24412547]
Kind
Protein
Organism
Human immunodeficiency virus 1
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Rna-dna hybrid ribonuclease activity
Specific Function
Not Available
Gene Name
pol
Uniprot ID
Q72547
Uniprot Name
Reverse transcriptase/RNaseH
Molecular Weight
65223.615 Da
References
  1. Esposito F, Carli I, Del Vecchio C, Xu L, Corona A, Grandi N, Piano D, Maccioni E, Distinto S, Parolin C, Tramontano E: Sennoside A, derived from the traditional chinese medicine plant Rheum L., is a new dual HIV-1 inhibitor effective on HIV-1 replication. Phytomedicine. 2016 Nov 15;23(12):1383-1391. doi: 10.1016/j.phymed.2016.08.001. Epub 2016 Aug 10. [PubMed:27765358]

Drug created on February 10, 2016 09:40 / Updated on July 11, 2020 00:05

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates